BACKGROUND INFORMATION ON THE PROCEDURE 
1 
Submission of the dossier 
The applicant Glaxo Group Limited submitted on 26 May 2006 an application for Marketing 
Authorisation to the European Medicines Agency (EMEA) through the centralized procedure for 
Atriance, which was designated as an orphan medicinal product EU/3/05/293 on 16 June 2005. 
Atriance was designated as an orphan medicinal product in the following indication:  Treatment of 
acute lymphoblastic leukaemia. The calculated prevalence of this condition was 1.1 per 10,000 EU 
populations. 
The legal basis for this application refers to Article 8.3 of Directive 2001/83/EC, as amended - 
complete and independent application 
The application submitted is a complete dossier composed of administrative information, complete 
quality data, non-clinical and clinical data based on applicants’ own tests and studies and/or 
bibliographic literature substituting/supporting certain tests or studies. 
The applicant applied for the following indication: treatment of patients with T-cell acute 
lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has 
not responded to or has relapsed following treatment with at least two chemotherapy regimens. 
Information relating to Orphan Market Exclusivity 
Similarity 
Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) 
No 847/2000, the application contained a critical report addressing the possible similarity with 
authorised orphan medicinal products Evoltra, Glivec and Sprycel. 
Protocol Assistance: 
The applicant received Protocol Assistance from the CHMP on 27 January 2006. The Protocol 
Assistance pertained to insert quality and clinical aspects of the dossier.  
Licensing status: 
Atriance has been given a Marketing Authorisation in the USA on 28 October 2005. 
A new application was filed in the following country: Canada 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Jens Ersbøll 
Co-Rapporteur: Barbara van Zwieten-Boot 
2 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 26 May 2006. 
The procedure started on 21 June 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  13 
September  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 19 September 2006.   
During  the  meeting  on  16-19  October  2006  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 20 October 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  16 
February 2007. 
1/2 
© EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 18 April 2007. 
During  the  CHMP  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and in an oral explanation by the applicant.  
The CHMP adopted a report on similarity of Atriance with Evoltra, Sprycel and Glivec on 26 
April 2007. 
During  the  CHMP  meeting  on  21-24  May  2007,  outstanding  issues  were  addressed  by  the 
applicant during an oral explanation before the CHMP. 
During the meeting on 18-21 June 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  under  exceptional  circumstances  to  Atriance  on  21  June  2007.  The 
applicant provided the letter of undertaking on the specific obligations and follow-up measures 
to be fulfilled post-authorisation on 18 June 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 22 August 2007. 
2/2 
© EMEA 2007 
